Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 3/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.44 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
| ▸ | CASR | P41180 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21925191 | 0.87 | LNPEP (0.53) | GAAMAPTKDM4EALDH1A1ERAP2 | |
| SCHEMBL26500612 | 0.85 | GAA (0.40) | PTGER4ALOX15ALOX5GAAMAPT | |
| SCHEMBL4341372 | 0.84 | ALOX15 (0.63) | PTGER4ALOX15GAAMAPTCYP1A2 | |
| SCHEMBL15319909 | 0.80 | GAA (0.65) | PTGER4ALOX15GAAMAPTKDM4E | |
| SCHEMBL11256349 | 0.79 | SMN1; SMN2 (0.59) | ALOX5GAAMAPTLMNAKDM4E | |
| SCHEMBL8040417 | 0.79 | PPARG (0.49) | LMNAKDM4EALDH1A1HDAC3HDAC1 | |
| SCHEMBL10389937 | 0.79 | MAPT (0.56) | ALOX5MAPTCYP1A2LMNAKDM4E | |
| SCHEMBL19922649 | 0.79 | MAPT (0.56) | ALOX5MAPTCYP1A2LMNAKDM4E | |
| SCHEMBL31159571 | 0.78 | PTGER4 (0.60) | PTGER4ALOX15GAAMAPTCYP1A2 | |
| SCHEMBL408918 | 0.77 | PTGER4 (0.67) | PTGER4ALOX15GAAMAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230324359-A1 | THERAPEUTIC DRUG FOR LIPID-PEROXIDATION-INDUCED DISEASES AND SCREENING METHOD FOR THERAPEUTIC DRUGS FOR LIPID-PEROXIDATION-INDUCED DISEASES | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2023-10-12 | — | — | US | disclosed |
| US-20230324358-A1 | THERAPEUTIC DRUG FOR LIPID-PEROXIDATION-INDUCED DISEASES AND SCREENING METHOD FOR THERAPEUTIC DRUGS FOR LIPID-PEROXIDATION-INDUCED DISEASES | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2023-10-12 | — | — | US | disclosed |
| US-20230324358-A1 | THERAPEUTIC DRUG FOR LIPID-PEROXIDATION-INDUCED DISEASES AND SCREENING METHOD FOR THERAPEUTIC DRUGS FOR LIPID-PEROXIDATION-INDUCED DISEASES | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2023-10-12 | — | — | US | disclosed |
| US-11519893-B2 | Therapeutic drug for lipid-peroxidation-induced diseases and screening method for therapeutic drugs for lipid-peroxidation-induced diseases | YAMADA, Ken-ichi (JP) | 2022-12-06 | — | — | US | disclosed |
| US-20220023283-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DEMENTIA AND CEREBROVASCULAR DISORDERS | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2022-01-27 | — | — | US | disclosed |
| WO-2020145364-A1 | PHARMACEUTICAL COMPOSITION FOR INTRAOCULAR OR ORAL ADMINISTRATION FOR TREATMENT OF RETINAL DISEASES | 山田 健一 | 2020-07-16 | — | — | WO | disclosed |
| WO-2020145359-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DEMENTIA AND CEREBROVASCULAR DISORDERS | 山田 健一 | 2020-07-16 | — | — | WO | disclosed |
| US-20200158709-A1 | THERAPEUTIC DRUG FOR LIPID-PEROXIDATION-INDUCED DISEASES AND SCREENING METHOD FOR THERAPEUTIC DRUGS FOR LIPID-PEROXIDATION-INDUCED DISEASES | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11519893-B2 | Therapeutic drug for lipid-peroxidation-induced diseases and screening method for therapeutic drugs for lipid-peroxidation-induced diseases | GPX4, GPX1, ALOX15 | PTGER4 327/4885ALOX15 3/4885ALOX5 4/4885 |
| US-20200158709-A1 | THERAPEUTIC DRUG FOR LIPID-PEROXIDATION-INDUCED DISEASES AND SCREENING METHOD FOR THERAPEUTIC DRUGS FOR LIPID-PEROXIDATION-INDUCED DISEASES | GPX4, GPX1, ALOX15 | PTGER4 327/4885ALOX15 3/4885ALOX5 4/4885 |
| US-20220023283-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DEMENTIA AND CEREBROVASCULAR DISORDERS | HTR3B, HTR3A, HTR2A | PTGER4 273/4885ALOX15 773/4885ALOX5 740/4885 |
| US-20230324358-A1 | THERAPEUTIC DRUG FOR LIPID-PEROXIDATION-INDUCED DISEASES AND SCREENING METHOD FOR THERAPEUTIC DRUGS FOR LIPID-PEROXIDATION-INDUCED DISEASES | GPX4, GPX1, ALOX15 | PTGER4 327/4885ALOX15 3/4885ALOX5 4/4885 |
| US-20230324359-A1 | THERAPEUTIC DRUG FOR LIPID-PEROXIDATION-INDUCED DISEASES AND SCREENING METHOD FOR THERAPEUTIC DRUGS FOR LIPID-PEROXIDATION-INDUCED DISEASES | GPX4, GPX1, ALOX15 | PTGER4 327/4885ALOX15 3/4885ALOX5 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.